BACKGROUND: Chemokines are a class of cytokines with chemotactic properties shown to be induced by M. tuberculosis or its antigens in vitro and in experimental infection in vivo. A few studies have also demonstrated the expression of chemokines in clinical samples of patients with active tuberculosis (TB). In the present work, we measured the concentration of chemokines in plasma samples of HIV-negative patients with pulmonary tuberculosis at different stages of chemotherapy. For comparison, we also evaluated the levels of sTNFR1 and TNF-alpha. METHODS: Cytokines and chemokines were measured by ELISA in healthy individuals and patients with active pulmonary TB at different stages of treatment. RESULTS: The concentrations of CXCL8, CXCL9 and sTNFR1 were elevated in patients with active pulmonary TB but returned to background levels at 4-6 months of chemotherapy. The concentration of CCL11 was elevated in patients with active pulmonary tuberculosis when compared to control and remained elevated throughout the specific therapy. There was no difference in the plasma concentration of CCL2 and CXCL10 between pulmonary TB patients and control subjects. CONCLUSION: Measurement of the CXCL8, CXCL9 and sTNFR1 may be useful to assess response to treatment in pulmonary TB patients.
BACKGROUND: Chemokines are a class of cytokines with chemotactic properties shown to be induced by M. tuberculosis or its antigens in vitro and in experimental infection in vivo. A few studies have also demonstrated the expression of chemokines in clinical samples of patients with active tuberculosis (TB). In the present work, we measured the concentration of chemokines in plasma samples of HIV-negative patients with pulmonary tuberculosis at different stages of chemotherapy. For comparison, we also evaluated the levels of sTNFR1 and TNF-alpha. METHODS: Cytokines and chemokines were measured by ELISA in healthy individuals and patients with active pulmonary TB at different stages of treatment. RESULTS: The concentrations of CXCL8, CXCL9 and sTNFR1 were elevated in patients with active pulmonary TB but returned to background levels at 4-6 months of chemotherapy. The concentration of CCL11 was elevated in patients with active pulmonary tuberculosis when compared to control and remained elevated throughout the specific therapy. There was no difference in the plasma concentration of CCL2 and CXCL10 between pulmonary TB patients and control subjects. CONCLUSION: Measurement of the CXCL8, CXCL9 and sTNFR1 may be useful to assess response to treatment in pulmonary TB patients.
Authors: Fernanda Matos Coelho; F M S Narciso; D M G Oliveira; D S Pereira; A L Teixeira; M M Teixeira; D G Souza; L S M Pereira Journal: Inflamm Res Date: 2009-08-22 Impact factor: 4.575
Authors: Mercedes Gonzalez-Juarrero; Luke C Kingry; Diane J Ordway; Marcela Henao-Tamayo; Marisa Harton; Randall J Basaraba; William H Hanneman; Ian M Orme; Richard A Slayden Journal: Am J Respir Cell Mol Biol Date: 2008-09-11 Impact factor: 6.914
Authors: Selvakumar Subbian; Liana Tsenova; Mi-Jeong Kim; Helen C Wainwright; Annalie Visser; Nirmalya Bandyopadhyay; Joel S Bader; Petros C Karakousis; Gabriele B Murrmann; Linda-Gail Bekker; David G Russell; Gilla Kaplan Journal: PLoS One Date: 2015-07-02 Impact factor: 3.240
Authors: Rosane Dias Costa; Vanessa Amaral Mendonça; Frederico Marianetti Soriani; Sandra Lyon; Rachel Adriana Penido; Ana Maria Duarte Dias Costa; Marina Dias Costa; Fabio de Souza Terra; Mauro Martins Teixeira; Carlos Mauricio de Figueiredo Antunes; Antonio Lúcio Teixeira Journal: Mem Inst Oswaldo Cruz Date: 2013-12 Impact factor: 2.743
Authors: Grace Lui; Chun Kwok Wong; Margaret Ip; Yi Jun Chu; Irene M H Yung; Catherine S K Cheung; Lin Zheng; Judy S Y Lam; Ka Tak Wong; Winnie W Y Sin; Kin Wing Choi; Nelson Lee Journal: PLoS One Date: 2016-07-19 Impact factor: 3.240